abt-199 has been researched along with Paraproteinemias* in 2 studies
1 review(s) available for abt-199 and Paraproteinemias
| Article | Year |
|---|---|
How do we manage t(11;14) plasma cell disorders with venetoclax?
The oral BCL-2 inhibitor venetoclax has demonstrated promising efficacy in patients with t(11;14) plasma cell disorders, both as a single-agent and in combination. However, there was an increased mortality signal in the randomized BELLINI trial that was primarily driven by non-t(11;14) patients. Based on current evidence, venetoclax is included as an option for relapsed/refractory t(11;14) plasma cell dyscrasias in NCCN guidelines and is being widely used in clinical practice. In this review, we aim to critically appraise the current literature and perform case-based illustration of our approach to management of t(11;14) plasma cell disorders with venetoclax. Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Humans; Paraproteinemias; Plasma Cells; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Treatment Outcome | 2022 |
1 other study(ies) available for abt-199 and Paraproteinemias
| Article | Year |
|---|---|
The impact of anti-bacterial prophylaxis on the outcome of patients treated with venetoclax-based regimens for relapsed/refractory plasma cell dyscrasias: Real-life data.
Topics: Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paraproteinemias; Prognosis; Retrospective Studies; Salvage Therapy; Sulfonamides; Survival Rate | 2020 |